Moleculin Biotech, Inc. shares new research showing its drug Annamycin fights pancreatic cancer.

Sep 25, 2026, 1:08 PM ETTrialRead the original at SEC EDGAR

Neutral

Moleculin's lab findings suggest Annamycin's cancer-fighting activity partly involves immune cells, but they do not show benefit in people. A previous report also said Nasdaq might remove its shares because their price was too low, leaving the picture mixed.

MBRX · Moleculin Biotech, Inc.

AI read · Neutral

The AI's read

This adds a possible explanation for how Annamycin may fight pancreatic cancer, but it does not show that the drug helps patients. A previous report said Nasdaq might remove Moleculin's shares because their price was too low. The early lab result and the possible listing loss point in different directions.

Get alerts for MBRX

Follow Moleculin Biotech, Inc. (MBRX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for MBRX

Free on the App Store and Google Play, or on the web.